 Patients will be treated with 1x10e6 re-directed FAP-specific T cells injected in the pleural effusion. The study ends 35 days after adoptive T cell transfer. Re-directed FAP-specific T cells will be administered at day 0 day 14 of the third cycle of palliative chemotherapy. The study is designed to demonstrate safety of 1x10e6 re-directed FAP-specific T cells. The next patient will be enrolled earliest, when the previous patient completed day 14 and the safety monitoring board has not declared any DLTs. The palliative chemotherapy is not part of the study protocol. 